We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Coleman is an entrepreneurial synthetic biologist who co-found Codagenix, Inc. to commercialize their genome design platform for vaccine development – helping to raise $14M and securing partnerships in the Agricultural vaccine space. Dr. Coleman led Codagenix’s Influenza vaccine candidate from bench to bedside, where it is currently being tested in Phase I/II human trials. Dr. Coleman leads all aspects of the Codagenix business and oversees the strategic advancement of its pipeline of vaccines including: Zika, RSV, Dengue, and other targets. Dr. Coleman is a skilled and creative microbiologist who has made pivotal advances in synthetic biology (Science 2008). His work possesses a unique vision and he is passionate about utilizing rational gene design to solve pertinent medical issues and emergent bio-threats. He has a BS from Tulane University, a PhD from Stony Brook University, and a MBA from
This speaker's sessions: